ALZN (Alzamend Neuro) Tariff Resilience Score: 8/10 (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALZN Alzamend Neuro Inc ALZN
21 GF Score
Price $1.33
! 1 Warning Sign
View Full Analysis

What is Alzamend Neuro Tariff Resilience Score?

Alzamend Neuro ALZN +0.75% 21 Tariff Resilience Score is 8 as of Jul. 27, 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,367 Biotechnology companies, Alzamend Neuro ranks better than 98.68% on this metric.

Alzamend Neuro has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Alzamend Neuro has Primarily focused on biotechnology with minimal exposure to international supply chains. Limited manufacturing dependencies and sales are mostly domestic, reducing tariff impact.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Alzamend Neuro might have Highly Resilient.

Alzamend Neuro  (NAS:ALZN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Alzamend Neuro Tariff Resilience Score Related Terms

ALZN vs SILO, BGMS, ENVB: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Alzamend Neuro's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzamend Neuro Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's Tariff Resilience Score falls into.


ALZN
21GF Score
Alzamend Neuro Inc ALZN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Alzamend Neuro (ALZN) has a Tariff Resilience Score of 8 as of Jul. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Alzamend Neuro ranks #18 out of 1367 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Alzamend Neuro's Tariff Resilience Score too high?
Alzamend Neuro's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Alzamend Neuro's value of 8 is 100% above this industry median. Based on the distribution chart, Alzamend Neuro ranks #18 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's Tariff Resilience Score compare to SILO and BGMS?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #18 out of 1367 companies for Tariff Resilience Score. This places Alzamend Neuro in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Alzamend Neuro's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alzamend Neuro's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alzamend Neuro's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current Tariff Resilience Score is 8 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzamend Neuro Business Description

Address 3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score

Get the complete analysis for ALZN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price